How to buy Ocugen shares | US$0.22

Own your own OCGN stock in just a few minutes.

Posted

Fact checked

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

US$0.22
current price
US$0.011
change
5.213%
change %

How to buy stock in Ocugen

  1. Compare share trading platforms. To buy shares in a US company from New Zealand you’ll need to find a trading platform that offers access to US stock markets. If you’re just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, including your ID. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Ocugen. Find the share by name or ticker symbol: OCGN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Ocugen reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price of US$0.22, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Ocugen, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Ocugen. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
  7. Price details for Ocugen (OCGN)

    Open $0.222 Previous close $0.2091
    High $0.2238 Change $0.011
    Low $0.2134 Change % 5.213%
    Close $0.22 Timestamp 1594324800
    Volume N/A GMT offset 0

    Ocugen stock price

    Use our graph to track the performance of OCGN stocks over time.

    Compare share trading platforms

    Data indicated here is updated regularly
    Name Product Monthly fee Currency conversion fee Available markets
    Stake
    $0
    1% ($2 min)
    NASDAQ
    NYSE
    BATS
    Chicago Stock Exchange
    And more
    Sign up through Finder and use referral code "FINDERNZ" for a free stock. Trade 3,500 US listed stocks and ETFs through Stake with $0 brokerage.
    loading

    Compare up to 4 providers

    The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

    Ocugen company summary

    Information last updated 2020-06-26.

    Ocugen (OCGN) is a leading Biotechnology business based in the USA. Ocugen (OCGN) is listed on the NASDAQ and employs 16 staff.

    Profile

    Industry Biotechnology Currency symbol $
    Code OCGN Country name USA
    Type Common Stock Country ISO US
    Name Ocugen, Inc ISIN N/A
    Exchange NASDAQ CUSIP N/A
    Currency code USD Sector Healthcare
    Currency name US Dollar Full-time employees 16

    Detailed company information

    Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. Ocugen, Inc. is based in Malvern, Pennsylvania.

    Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
Go to site